KR20230107551A - 융합된 헤테로아릴 화합물 및 camkii 억제제로서의 그의 용도 - Google Patents

융합된 헤테로아릴 화합물 및 camkii 억제제로서의 그의 용도 Download PDF

Info

Publication number
KR20230107551A
KR20230107551A KR1020237014351A KR20237014351A KR20230107551A KR 20230107551 A KR20230107551 A KR 20230107551A KR 1020237014351 A KR1020237014351 A KR 1020237014351A KR 20237014351 A KR20237014351 A KR 20237014351A KR 20230107551 A KR20230107551 A KR 20230107551A
Authority
KR
South Korea
Prior art keywords
group
optionally substituted
alkyl
groups
mono
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237014351A
Other languages
English (en)
Korean (ko)
Inventor
노부유키 마츠나가
준야 시라이
도모히로 오카와
야스후미 미야모토
젠유 시오카와
다카시 나카하타
아키토 시부야
아키라 가와다
맬컴 맥코스
Original Assignee
카듀리온 파마슈티칼스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 카듀리온 파마슈티칼스, 인크. filed Critical 카듀리온 파마슈티칼스, 인크.
Publication of KR20230107551A publication Critical patent/KR20230107551A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
KR1020237014351A 2020-09-28 2021-09-24 융합된 헤테로아릴 화합물 및 camkii 억제제로서의 그의 용도 Pending KR20230107551A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063084217P 2020-09-28 2020-09-28
US63/084,217 2020-09-28
PCT/US2021/052025 WO2022067082A1 (en) 2020-09-28 2021-09-24 Fused heteroaryl compounds and their use as camkii inhibitors

Publications (1)

Publication Number Publication Date
KR20230107551A true KR20230107551A (ko) 2023-07-17

Family

ID=80821052

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237014351A Pending KR20230107551A (ko) 2020-09-28 2021-09-24 융합된 헤테로아릴 화합물 및 camkii 억제제로서의 그의 용도

Country Status (14)

Country Link
US (2) US11795172B2 (enExample)
EP (1) EP4216948A4 (enExample)
JP (1) JP7824282B2 (enExample)
KR (1) KR20230107551A (enExample)
CN (1) CN116940354A (enExample)
AU (1) AU2021350015A1 (enExample)
CA (1) CA3196946A1 (enExample)
CL (1) CL2023000894A1 (enExample)
CO (1) CO2023005189A2 (enExample)
IL (1) IL301480A (enExample)
MX (1) MX2023003610A (enExample)
PE (1) PE20240148A1 (enExample)
TW (1) TW202229273A (enExample)
WO (1) WO2022067082A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7824282B2 (ja) * 2020-09-28 2026-03-04 カーデュリオン・ファーマシューティカルズ・インコーポレイテッド 縮合ヘテロアリール化合物およびＣａＭＫＩＩ阻害剤としてのその使用
WO2023134692A1 (zh) * 2022-01-13 2023-07-20 浙江同源康医药股份有限公司 多环类化合物及其用途
CN115160235B (zh) * 2022-08-10 2023-12-15 宜宾学院 一种2,3-二氢喹唑啉-4(1h)-酮类化合物及其超声合成方法
US20250145630A1 (en) * 2023-11-07 2025-05-08 Cardurion Pharmaceuticals, Inc. Polymorphs of a pyridinylimidazo[1,2-b]pyridazine

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1317266A2 (en) 2000-08-08 2003-06-11 Ortho-McNeil Pharmaceutical, Inc. Neuroprotective 2-pyridinamine compositions and related methods
HK1054393B (en) 2000-09-20 2009-08-28 Ortho-Mcneil Pharmaceutical, Inc. Pyrazine derivatives as modulators of tyrosine kinases
US20030187026A1 (en) * 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
JP2007504229A (ja) 2003-09-02 2007-03-01 メルク　エンド　カムパニー　インコーポレーテッド 代謝調節型グルタミン酸受容体−５のモジュレーターとしてのビピリジルアミン類およびエーテル類
US7776857B2 (en) 2007-04-05 2010-08-17 Amgen Inc. Aurora kinase modulators and method of use
US9216173B2 (en) 2011-10-05 2015-12-22 Merck Sharp & Dohme Corp. 2-Pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors
HRP20180037T1 (hr) 2012-04-17 2018-03-23 Fujifilm Corporation Heterociklični spoj koji sadrži dušik ili njegovu sol
CA2894126A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
CN107074856A (zh) * 2014-09-05 2017-08-18 阿略斯泰罗斯医疗公司 CaMKII抑制剂及其用途
AR110252A1 (es) 2016-11-30 2019-03-13 Gilead Sciences Inc Compuestos heterocíclicos fusionados como inhibidores de la quinasa cam
CN110799190B (zh) 2017-03-27 2024-04-19 卡都瑞恩医药有限公司 杂环化合物
JP7447098B2 (ja) 2018-09-25 2024-03-11 カーデュリオン・ファーマシューティカルズ・インコーポレイテッド アミノピリミジン化合物
WO2020068846A1 (en) * 2018-09-25 2020-04-02 Heterocyclic Compound Heterocyclic compound
US20230000842A1 (en) 2019-01-17 2023-01-05 Samumed, Llc Methods of treating cartilage disorders through inhibition of clk and dyrk
JP7824282B2 (ja) * 2020-09-28 2026-03-04 カーデュリオン・ファーマシューティカルズ・インコーポレイテッド 縮合ヘテロアリール化合物およびＣａＭＫＩＩ阻害剤としてのその使用

Also Published As

Publication number Publication date
AU2021350015A1 (en) 2023-06-08
EP4216948A1 (en) 2023-08-02
JP7824282B2 (ja) 2026-03-04
CN116940354A (zh) 2023-10-24
IL301480A (en) 2023-05-01
US12528816B2 (en) 2026-01-20
US20220098207A1 (en) 2022-03-31
JP2023543038A (ja) 2023-10-12
CL2023000894A1 (es) 2023-09-15
PE20240148A1 (es) 2024-02-06
AU2021350015A9 (en) 2024-10-03
MX2023003610A (es) 2023-07-20
TW202229273A (zh) 2022-08-01
CA3196946A1 (en) 2022-03-31
WO2022067082A1 (en) 2022-03-31
CO2023005189A2 (es) 2023-08-09
US20240182474A1 (en) 2024-06-06
US11795172B2 (en) 2023-10-24
EP4216948A4 (en) 2024-08-28

Similar Documents

Publication Publication Date Title
KR102638678B1 (ko) 헤테로시클릭 화합물
CN109790122B (zh) 杂环化合物
JP7824282B2 (ja) 縮合ヘテロアリール化合物およびＣａＭＫＩＩ阻害剤としてのその使用
EA026385B1 (ru) Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов
CN111918863B (zh) 杂环化合物
EP4188930A1 (en) Substituted heterocyclic compounds and therapeutic uses thereof
US10519110B2 (en) Heterocyclic compound
JP2022507858A (ja) Ｉｒａｋ４阻害剤としての新規な三環式化合物
KR102946104B1 (ko) 아미노피리미딘 화합물
JP2017222626A (ja) 複素環化合物
EA052559B1 (ru) Конденсированные гетероарильные соединения и их применение в качестве ингибиторов camkii
EP3514149B1 (en) Heterocyclic amide compound
NZ728416B2 (en) 2-(morpholin-4-yl)-1,7-naphthyridines

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902